Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCLEROLUNG: Fractalkine in SSc-ILD
NCT03508375Unknown
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- May 2018
- Primary completion
- May 2021
- Countries
- 1
01
Overview
Open-label trial (3 arms), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoint: Serum soluble fractalkine levels at 24 months. Status: unknown.
Beyond the preview
Go deeper on NCT03508375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03508375.